Wnt/β-catenin agonist 1
Based on 9 publication(s) in Google Scholar
Wnt/β-catenin agonist 1 (compound 3f) is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM.
For research use only. We do not sell to patients.
- Purity: 99.72%
- CAS No.: 2305372-67-0
- Formula: C22H25N3O2
- Molecular Weight:363.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Cytoskeleton Compound Library
HY-L060
-
Neuroprotective Compound Library
HY-L070
-
Anti-Obesity Compound Library
HY-L087
-
Antidepressant Compound Library
HY-L108
-
Osteogenesis Compound Library
HY-L131
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Wnt/β-catenin agonist 1
More- Cell Death Discov. 2022 Oct 1;8(1):404. [Abstract]
- Aging Cell. 2022 Aug;21(8):e13677. [Abstract]
- JCI Insight. 2026 Jan 27:e201552. [Abstract]
- Drug Dev Res. 2026 May;87(3):e70300. [Abstract]
- Front Biosci (Landmark Ed). 2024 Jan 17;29(1):15. [Abstract]
- Cancer Manag Res. 2025 Dec 22:17:3227-3240. [Abstract]
- Cancer Manag Res. 2020 Sep 28:12:9197-9209. [Abstract]
- bioRxiv. 2025 Oct 22.
- Res Sq. 2025 Oct 12.
Biological Activity
EC50: 0.27 μM (Wnt/β-catenin)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2305372-67-0
-
Appearance Solid
-
Molecular Weight 363.45
-
Formula C22H25N3O2
-
Color White to light yellow
-
SMILES
CCN1CC2=CC(OCC3=CC(C)=NN3C)=C(O)C=C2C4=C1C(C)=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Discov
Sevoflurane induces microRNA-18a to delay rat neurodevelopment via suppression of the RUNX1/Wnt/β-catenin axis. [Abstract]2022 Oct 1;8(1):404. PMID: 36182925 -
Aging Cell
p300 arrests intervertebral disc degeneration by regulating the FOXO3/Sirt1/Wnt/β-catenin axis. [Abstract]2022 Aug;21(8):e13677. PMID: 35907249 -
JCI Insight
β-Catenin Stabilization Protects Against Alveolar Hemorrhage Through Amphiregulin and BATF-Mediated Regulatory T Cells. [Abstract]2026 Jan 27:e201552. PMID: 41591823 -
Drug Dev Res
MORC2 Recruits Tumor-Associated Macrophages and Inhibits Pyroptosis Through Activating the Wnt/β-Catenin Pathway in Breast Cancer. [Abstract]2026 May;87(3):e70300. PMID: 42145133 -
Front Biosci (Landmark Ed)
Huaier Regulates Oxaliplatin Resistance in Colorectal Cancer by Regulating Autophagy and Inhibiting the Wnt/β-catenin Signalling Pathway. [Abstract]2024 Jan 17;29(1):15. PMID: 38287798 -
Cancer Manag Res
ALPP Induces Epithelial-Mesenchymal Transition by Activating the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer Cells. [Abstract]2025 Dec 22:17:3227-3240. PMID: 41459136 -
Cancer Manag Res
microRNA-139-3p Inhibits Malignant Behaviors of Laryngeal Cancer Cells via the KDM5B/SOX2 Axis and the Wnt/β-Catenin Pathway. [Abstract]2020 Sep 28:12:9197-9209. PMID: 33061611 -
-
Solvent & Solubility
DMSO : 10 mg/mL (27.51 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7514 mL | 13.7571 mL | 27.5141 mL | 68.7853 mL |
| 5 mM | 0.5503 mL | 2.7514 mL | 5.5028 mL | 13.7571 mL | |
| 10 mM | 0.2751 mL | 1.3757 mL | 2.7514 mL | 6.8785 mL | |
| 15 mM | 0.1834 mL | 0.9171 mL | 1.8343 mL | 4.5857 mL | |
| 20 mM | 0.1376 mL | 0.6879 mL | 1.3757 mL | 3.4393 mL | |
| 25 mM | 0.1101 mL | 0.5503 mL | 1.1006 mL | 2.7514 mL |
Wnt/β-catenin agonist 1 Related Classifications
HY-114321 Related Classifications
Powered by Bioz